Sign In
Buy BNTX
$90.58
-2.27 (-2.44%)
At Close: Jul 31, 2026
Global interim Phase 2 data in locally advanced/metastatic triple-negative breast cancer (”TNBC”) show encouraging antitumor activity for investigational therapy pumitamig (BNT327/BMS986545) plus
Gotistobart demonstrated a clinically meaningful overall survival benefit compared to standard chemotherapy and a manageable safety profile in sqNSCLC
BioNTech Achieves Minimum Condition in CureVac Exchange Offer
09:01am, Wednesday, 03'rd Dec 2025
The minimum condition for the offer has been satisfied, with 184,071,410 shares of CureVac, representing approximately 81.74% of CureVac's issued and outstanding shares, tendered prior to the expirati
Dow Jones Today: Stock Indexes Close Lower to Begin December Trading; Big Tech, Crypto-Tied Shares Drop Amid Risk-Off Sentiment
08:00pm, Monday, 01'st Dec 2025
Major stock indexes pulled back as the final trading month of the year began, with shares of big tech and cryptocurrency-tied firms falling amid risk-off sentiment.
Market Today: Crypto Rout, Omnicom Cuts, Nvidia--Synopsys Deal
06:17pm, Monday, 01'st Dec 2025
Guru Stock PicksRoyce International Premier Fund has made the following transactions:Reduce in XTER: EVD by 0.78%Sold out in ASX:JLGAdd in XPAR: PLNW by 62.41%New
FDA Plans to Tighten Vaccine Approvals Weigh on These Stocks
03:50pm, Monday, 01'st Dec 2025
A report that vaccine approvals could be set to get stricter is pressuring shares of major vaccine makers.
Vaccine stocks take a hit as FDA official points to link between COVID-19 vaccines and rare heart condition in young men
12:35pm, Monday, 01'st Dec 2025
Memo also reportedly mentions vaccines for flu and pneumonia.
Moderna and Novavax Stocks Drop as FDA Proposes Stricter Vaccine Approvals
09:59am, Monday, 01'st Dec 2025
The FDA's top vaccine regulator outlines proposed changes to the vaccine evaluation process in an internal memo.
BioNTech Shares Progress on Exchange Offer for CureVac Shares and Highlights December 3, 2025, at 9:00 a.m. Eastern Time Expiration
07:30am, Wednesday, 26'th Nov 2025
MAINZ, Germany, November 26, 2025 – BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced the approval of matters relating to the exchange offer (the “Offer”) for all outstanding shares of
BioNTech SE ( BNTX ) Discusses Oncology Innovation Strategy, Combination Therapies and Personalized Cancer Immunotherapies November 11, 2025 9:00 AM EST Company Participants Ugur Sahin - Co-Founder, C
Allianz SE Buys 5,080 Shares of BioNTech SE Sponsored ADR $BNTX
04:03am, Friday, 14'th Nov 2025
Allianz SE grew its position in BioNTech SE Sponsored ADR (NASDAQ: BNTX) by 635.0% in the second quarter, according to its most recent filing with the SEC. The fund owned 5,880 shares of the company's
Pfizer sheds BioNTech stake years after blockbuster COVID vaccine tie-up
05:20pm, Thursday, 13'th Nov 2025
Pfizer Inc said on Thursday said that it will sell 54.7% of its stake in German drugmaker BioNTech SE , over five years after both firms formed an alliance that yielded a vaccine to combat the deadly
Pfizer Seeks To Exit BioNTech Investment After Lucrative Covid Vaccine Run
11:10am, Thursday, 13'th Nov 2025
Pfizer (NYSE: PFE) is reportedly offloading its remaining stake in Covid-19 vaccine partner BioNTech SE (NASDAQ: BNTX).
BioNTech says collaboration with Pfizer remains unchanged
08:17am, Thursday, 13'th Nov 2025
BioNTech said on Thursday that its collaboration with Pfizer has not changed, when asked to comment on a report that Pfizer is looking to sell its stake in the German biotech firm.
BioNTech Q3 Earnings: Plenty Of Cash And Pipeline Potential, But Still A Hold
01:44pm, Monday, 03'rd Nov 2025
BioNTech SE shared its Q3 earnings, business updates, and guidance for 2025 earlier today. Its share price is down 1% in trading so far. BNTX maintains a strong cash position, driven by ongoing Comirn
